Abbvie (ABBV) Earnings (2012 - 2026)
Abbvie (ABBV) earnings from Mar 31, 2012 to Mar 31, 2026. The TTM Abbvie (ABBV) earnings is $3.63B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Earnings
Quarterly Earnings
Abbvie (ABBV) Earnings CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -13.35% |
| 3 Years TTM | -21.74% |
| 5 Years TTM | -6.76% |
| 10 Years TTM | -4.01% |
| All Time TTM | -2.94% |
Annual Earnings change of Abbvie (ABBV)
| Year | Earnings | Change |
|---|---|---|
| 2026 | $695M | -83.55% |
| 2025 | $4.23B | -1.22% |
| 2024 | $4.28B | -12.03% |
| 2023 | $4.86B | -58.91% |
| 2022 | $12B | +2.55% |
| 2021 | $12B | +150.04% |
| 2020 | $4.62B | -41.44% |
| 2019 | $7.88B | +38.60% |
| 2018 | $5.69B | +7.12% |
| 2017 | $5.31B | -10.82% |
| 2016 | $5.95B | +15.73% |
| 2015 | $5.14B | +189.97% |
| 2014 | $1.77B | -57.03% |
| 2013 | $4.13B | -21.74% |
| 2012 | $5.28B | +53.66% |
| 2011 | $3.43B | N/A |
Comparison Abbvie (ABBV) five years earnings CAGR with competitors
Abbvie (ABBV) five years earnings CAGR is -6.76%.
| Ticker | Name | five years Earnings CAGR | Upside |
|---|---|---|---|
| GILD | Gilead Sciences Inc | 98.24% | -1552.61% |
| LLY | Lilly(Eli) & Company | 32.92% | -586.74% |
| NVO | Novo Nordisk | 23.10% | -441.63% |
| AZN | Astrazeneca plc | 21.17% | -413.06% |
| NVS | Novartis AG | 11.21% | -265.80% |
| JNJ | Johnson & Johnson | 6.84% | -201.11% |
| MRK | Merck & Co Inc | 4.92% | -172.77% |
| GSK | GSK Plc | 2.84% | -142.04% |
| AMGN | AMGEN Inc | 1.94% | -128.71% |